Efficiency, safety and tolerabilitygenetic engineering biological preparation adalimumab in patients with rheumatoid arthritis
Автор: Mezenova T.V., Jurin T.O., Usacheva Yu.V., Tyurin V.P., Elonakov A.V.
Журнал: Вестник Национального медико-хирургического центра им. Н.И. Пирогова @vestnik-pirogov-center
Рубрика: Оригинальные статьи
Статья в выпуске: 3 т.8, 2013 года.
Бесплатный доступ
The article presents the efficacy, safety and tolerability of ТNFα inhibitor adalimumab in 35 patients with rheumatoid arthritis. Shown to be highly effective and well tolerated. Adverse events were established in 30.4% of patients, the most frequent of which were elevated levels of transaminase (16,1%) and creatinine (14,3%).
Rheumatoid arthritis, тnfα inhibitor, adalimumab
Короткий адрес: https://sciup.org/140188219
IDR: 140188219
Статья научная
